A Prospective Comparative Study of Two Regimens of Diphenylcyclopropenone (Dpcp) in the Treatment of Alopecia Areata

A Prospective Comparative Study of Two Regimens of Diphenylcyclopropenone (Dpcp) in the Treatment of Alopecia Areata Publisher Pubmed

Al Bazzal A¹ ; Hatami P¹ ; Abedini R^{1, 2} ; Etesami I^{1, 2} ; Ayanian Z^{1, 3} ; Ghandi N^{1, 2}

Show Affiliations

1. Autoimmune Bullous Diseases Research Center, Tehran University of Medical Sciences, Tehran, 1199663911, Iran
2. Department of Dermatology, School of Medicine Razi Hospital, Tehran University of Medical Sciences, Tehran, 1199663911, Iran
3. Department of Dermatology, Babol University of Medical Sciences, Babol, 47176_47745, Iran

Source: International Immunopharmacology Published:2021

Abstract

Background: Alopecia areata (AA) is a chronic disorder and the best treatment regimen for it is unknown. Currently, one of the best documented treatment modalities for AA is topical immunotherapy. Aim: To evaluate the safety and efficacy of a novel method (multi-concentration patch test) versus standard protocol for topical immunotherapy. Methods: A prospective randomized clinical trial was conducted on 30 patients with Alopecia areata, half of them received DPCP with a novel method using multi-concentration patch test to determine the optimal initiating concentration of DPCP (case group) and the other half experienced immunotherapy according to the standard protocol (control group). Percentage of hair regrowth after 6 months of treatment and the incidence of drug-related adverse effects were evaluated and compared between the two groups. (IRCT registration code: IRCT20141209020250N5). Results: Absolute and relative hair regrowth percentages were reported 25% and 41.49% in case group and 8.2% and 14.21% in control group respectively. Considerable response (more than 75% hair regrowth) was observed in 4 (26.6%) patients in case and 1 (6.6%) patient in control group. The clinical response was initiated about 7 weeks sooner in case compared to the control group (14 versus 7.38 weeks, P: 0.001). Overall, clinical response was higher in patients received new protocol, compared to control group. Moreover, patients who experienced new protocol had a higher level of treatment satisfaction in comparison with patients having standard protocol (P: 0.012). Conclusion: This study revealed the effectiveness and safety of the novel multi-concentration patch test DPCP therapy for AA and its priority to conventional method, at least in terms of shortened duration of DPCP immunotherapy. © 2021 Elsevier B.V.

Related Docs

View other Related Docs

1. A Randomized Trial of Diphenylcyclopropenone (Dpcp) Combined With Anthralin Versus Dpcp Alone for Treating Moderate to Severe Alopecia Areata, International Immunopharmacology (2021)

2. Striae Gravidarum Treatment: Evaluating Non-Ablating Fractional Laser (Nafl) Efficacy and Safety, Journal of Cosmetic and Laser Therapy (2023)

3. Influence of Narrow-Band Ultra Violet B Phototherapy on Homocysteine Status: A Prospective Study of Patients With Different Cutaneous Disorders, Photobiomodulation# Photomedicine# and Laser Surgery (2021)

4. Topical Immunotherapy With Diphenylcyclopropenone in Paediatric Patients With Alopecia Areata—A Retrospective Study of 97 Patients, Skin Health and Disease (2024)

5. Multiple Cycles of Rituximab Therapy for Pemphigus: A Group of Patients With Difficult- To-Treat Disease or a Consequence of Late Rituximab Initiation?, Dermatologic Therapy (2022)

6. Punctate Pattern and Pemphigus: Is There Any Evidence of Punctate Pattern Among Iranian Patients?, American Journal of Dermatopathology (2022)

7. Covid Vaccination in Patients Under Treatment With Rituximab: A Presentation of Two Cases From Iran and a Review of the Current Knowledge With a Specific Focus on Pemphigus, Dermatologic Therapy (2022)

8. Serious Health Threat of Mucormycosis During the Ongoing Covid-19 Pandemic: What Dermatologists Need to Know in This Regard, International Journal of Dermatology (2022)

Experts (# of related papers)

View all Related Experts

Zeinab Aryanian (11)

Kamran Balighi (3)

Style	Citing Format
MLA	Al Bazzal A, et al.. "A Prospective Comparative Study of Two Regimens of Diphenylcyclopropenone (Dpcp) in the Treatment of Alopecia Areata." International Immunopharmacology, vol. 101, no. , 2021, pp. -.
APA	Al Bazzal A, Hatami P, Abedini R, Etesami I, Ayanian Z, Ghandi N (2021). A Prospective Comparative Study of Two Regimens of Diphenylcyclopropenone (Dpcp) in the Treatment of Alopecia Areata. International Immunopharmacology, 101(), -.
Chicago	Al Bazzal A, Hatami P, Abedini R, Etesami I, Ayanian Z, Ghandi N. "A Prospective Comparative Study of Two Regimens of Diphenylcyclopropenone (Dpcp) in the Treatment of Alopecia Areata." International Immunopharmacology 101, no. (2021): -.
Harvard	Al Bazzal A et al. (2021) 'A Prospective Comparative Study of Two Regimens of Diphenylcyclopropenone (Dpcp) in the Treatment of Alopecia Areata', International Immunopharmacology, 101(), pp. -.
Vancouver	Al Bazzal A, Hatami P, Abedini R, Etesami I, Ayanian Z, Ghandi N. A Prospective Comparative Study of Two Regimens of Diphenylcyclopropenone (Dpcp) in the Treatment of Alopecia Areata. International Immunopharmacology. 2021;101():-.
BibTex	@article{ author = {Al Bazzal A and Hatami P and Abedini R and Etesami I and Ayanian Z and Ghandi N}, title = {A Prospective Comparative Study of Two Regimens of Diphenylcyclopropenone (Dpcp) in the Treatment of Alopecia Areata}, journal = {International Immunopharmacology}, volume = {101}, number = {}, pages = {-}, year = {2021} }
RIS	TY - JOUR AU - Al Bazzal A AU - Hatami P AU - Abedini R AU - Etesami I AU - Ayanian Z AU - Ghandi N TI - A Prospective Comparative Study of Two Regimens of Diphenylcyclopropenone (Dpcp) in the Treatment of Alopecia Areata JO - International Immunopharmacology VL - 101 IS - SP - EP - PY - 2021 ER -

Science Communicator Platform

Authors

Authors Affiliations

Abstract